← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Revenue increased 230194.6% to $85.2M, while Net income increased 12.9% to ($140.1M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $85.2MWatch
- Profitability — Net income ($140.1M)Watch
- Cash generation — Free cash flow ($109.6M)Note
- Accounting — Formula-grey distress score · manipulation and earnings-quality screens not computedNote
- Insiders — 0 buys; 8 sells in 365 daysNote
- Capital — Comparable payout data unavailableNote
Business
4D Molecular Therapeutics, Inc.: We are in the late stages of drug development for our lead program and have a limited operating history and no products approved for commercial sale, which may make it difficult to evaluate our current business and predict our future success and viability.
Where the revenue comes from
Fiscal 2025, as 4D Molecular Therapeutics, Inc. reports it. History and quarterly detail are in the app.
- Collaboration And License Revenue$85.2M
Leadership changes
From 4D Molecular Therapeutics, Inc.'s own filings, the day they're filed.
- Kristian Humer · Principal Accounting Officer · appointmenteff. 2026-03-25
- Ashoo Gupta · Principal Financial Officer · appointmenteff. 2025-09-30
- Noriyuki Kasahara · Chief Scientific Officer · appointmenteff. 2024-01-02
Latest filings
- 10-Q · Quarterly report2026-08-13
- 8-K · Company announcement2026-08-13
- 8-K · Company announcement2026-07-20
- 8-K · Company announcement2026-06-29
- 8-K · Company announcement2026-06-22
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about 4D Molecular Therapeutics, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.